IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia
Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
Guide: Use of IDegAsp in T2D
Review practical recommendations from Australian diabetes experts on when and how to use IDegAsp (insulin degludec/insulin aspart) in real-world practice.
Podcast series: Improving care for patients with T2DM and the role of insulin
This series of podcasts aims to provide general practitioners (GPs) and other healthcare professionals with the latest clinically relevant information and opinions from experts in T2DM about the appropriate management of patients with T2DM in primary care, particularly regarding insulin therapy.
ThinkGP Live - IN Control workshop
Sydney | Melbourne | Brisbane | Gold Coast | Adelaide | Perth
ThinkGP Live returns in 2021 with workshops running throughout March in Sydney, Melbourne, Brisbane, Gold Coast, Adelaide & Perth. Full details now available!
Insulin therapy case study quiz
Select the best management options for a type 2 diabetes patient on insulin therapy in this case study quiz.
Recently published consensus statement: Practical guidance for the use of IDegAsp in type 2 diabetes
Dr Sarah Glastras provides practical advice on the usage of the insulin degludec/insulin aspart coformulation, and outlines its role in insulin initiation and intensification in light of the recently released consensus statement.
Optimising insulin for patients with type 2 diabetes in general practice
Diabetes is one of the most common chronic conditions in Australia today, and its management relies upon effective glycaemic control to minimise the risk of complications. This module aims to improve GP understanding of how to optimise insulin in type 2 diabetes.
(Existing enrolments) IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia
Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
